

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**天津發展控股有限公司**  
**TIANJIN DEVELOPMENT HOLDINGS LIMITED**

*(Incorporated in Hong Kong with limited liability)*

**(Stock Code: 882)**

## **OVERSEAS REGULATORY ANNOUNCEMENT**

This announcement is made by Tianjin Development Holdings Limited (the “**Company**”) pursuant to Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rules 13.09 and 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Tianjin Lisheng Pharmaceutical Co., Ltd. (天津力生製藥股份有限公司) (“**Lisheng Pharmaceutical**”), an indirect non-wholly owned subsidiary of the Company, has published an announcement on the website of Shenzhen Stock Exchange ([www.szse.cn](http://www.szse.cn)) in respect of its indicative results for the year of 2021, full text of which is reproduced in the attachment of this announcement.

As at the date of this announcement, the Company indirectly holds approximately 34.41% of the issued share capital of Lisheng Pharmaceutical.

By Order of the Board  
**Tianjin Development Holdings Limited**  
**Wang Gang**  
*Chairman and Executive Director*

Hong Kong, 22 January 2022

*As at the date of this announcement, the Board of the Company consists of Mr. Wang Gang, Dr. Li Xiaoguang, Mr. Zhuang Qifei, Mr. Cui Xiaofei\*, Mr. Cheung Wing Yui, Edward\*, Dr. Cheng Hon Kwan\*\*, Mr. Mak Kwai Wing, Alexander\*\*, Ms. Ng Yi Kum, Estella\*\*, Mr. Wong Shiu Hoi, Peter\*\* and Dr. Loke Yu\*\*.*

\* *non-executive director*

\*\* *independent non-executive director*

## TIANJIN LISHENG PHARMACEUTICAL CO., LTD.

### INDICATIVE RESULTS ANNOUNCEMENT FOR THE YEAR 2021

The Company and its directors, supervisors, and senior management warrant the truthfulness, accuracy and completeness of the contents of this announcement, and there are no false statements, misleading statements contained herein nor material omissions from this announcement.

#### I. INDICATIVE RESULTS FOR THE PERIOD

1. Period for the indicative results: 1 January 2021 to 31 December 2021
2. Indicative results:  Loss     Turnaround from loss     Increase over the corresponding period last year     Decrease over the corresponding period last year
3. Details of the indicative results

Item	Current reporting period	Corresponding period last year
Net profit attributable to the shareholders of the Company	Net profit: RMB 11000 to RMB 14000 (in ten thousand yuan)	Net profit: RMB 861.53 (in ten thousand yuan)
	Increased by approximately 1176.80% to 1525.02% as compared to the corresponding period last year	
Net profit after deducting the extraordinary gains or losses	Net profit: RMB 10600 to RMB 13700 (in ten thousand yuan)	Net profit: RMB 240.41 (in ten thousand yuan)
	Increased by approximately 4309.13% to 5598.60% as compared to the corresponding period last year	
Basic earnings per share	Earnings: RMB 0.60 per share to RMB 0.77 per share	Earnings: RMB 0.05 per share

#### II. COMMUNICATION WITH THE CERTIFIED PUBLIC ACCOUNTANTS

The relevant data related to the indicative results is based on the estimated calculation by the finance department of the Company and has not been audited by the certified public accountants. Regarding to the relevant matters related to the indicative results over the current reporting period, the Company has communicated with the certified public accountants for annual audit and there is no disagreement among us.

#### III. EXPLANATION FOR CHANGES IN RESULTS

1. Having faced the impact of novel coronavirus epidemic and changes of sector, the Company took effective measures to strengthen its budgetary control and cost containment so as to retrench expenditures in all aspects. Therefore, both selling and distribution expenses and general administrative expenses for 2021 significantly decreased. In 2021, interest revenue increased as compared with that of the previous year due to higher interest income derived from matured fixed deposits.

2. In 2020, the Company terminated the 23-valent pneumococcal polysaccharide vaccine project that an amount of RMB58,150,000 impairment provision had been made for the relevant assets, therefore a lower net profit base was recorded last year.

#### **IV. OTHER RELEVANT INFORMATION**

The data set out in the indicative results is based on the preliminary estimation by the finance department of the Company. The specific results data in details should be those disclosed in the Company's 2021 Annual Report. Investors are advised to exercise caution and pay attention to the investment risks involved.

The Board of Directors of  
Tianjin Lisheng Pharmaceutical Co., Ltd.  
22 January 2022